Inflammatory biomarkers as differential predictors of antidepressant response
Although antidepressants are generally effective in the treatment of major depressive disorder (MDD), it can still take weeks before patients feel the full antidepressant effects. Despite the efficacy of standard treatments, approximately two-thirds of patients with MDD fail to respond to pharmacoth...
Saved in:
Published in | International Journal of Molecular Sciences Vol. 16; no. 4; pp. 7796 - 7801 |
---|---|
Main Author | |
Format | Journal Article Book Review |
Language | English |
Published |
Switzerland
MDPI AG
08.04.2015
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Although antidepressants are generally effective in the treatment of major depressive disorder (MDD), it can still take weeks before patients feel the full antidepressant effects. Despite the efficacy of standard treatments, approximately two-thirds of patients with MDD fail to respond to pharmacotherapy. Therefore, the identification of blood biomarkers that can predict the treatment response to antidepressants would be highly useful in order to improve this situation. This article discusses inflammatory molecules as predictive biomarkers for antidepressant responses to several classes of antidepressants, including the N-methyl-d-aspartate (NMDA) receptor antagonist ketamine. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 1422-0067 1661-6596 1422-0067 |
DOI: | 10.3390/ijms16047796 |